Background-Impaired ␤-adrenergic receptor (AR)-mediated vasorelaxation in hypertension plays a role in increased peripheral vascular resistance and blood pressure. Because the ␤ 2 AR is the most abundant vascular AR subtype, we sought to enhance ␤AR vasorelaxation by overexpressing ␤ 2 ARs via adenoviral-mediated gene transfer (AD␤ 2 AR) to the vascular endothelium of the carotid artery. Methods and Results-In normotensive Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats, we exposed the right common carotid artery to AD␤ 2 AR in situ for 15 minutes by injection into the lumen while the blood flow was interrupted. Control carotids received an empty vector (ADempty). Three days later, transgene expression and selective endothelial localization were confirmed in infected vessels. Vasoregulation after ␤ 2 AR overexpression (2-fold) was studied in isolated organ baths. AD␤ 2 AR carotid responses to ␣ 1 AR and ␣ 2 AR agonists were not affected, whereas responses to epinephrine were altered and ␤AR-mediated vasorelaxation was enhanced after ␤ 2 AR overexpression. As expected, ␤AR-mediated vasodilatation in control carotids of SHR rats was significantly less than in similar control WKY carotid arteries. AD␤ 2 AR treatment enhanced ␤AR vasorelaxation in SHR to levels similar to those seen in AD␤ 2 AR WKY carotids. Conclusions-Our results demonstrate a critical role for the endothelium in ␤AR-mediated vasorelaxation and suggest that impaired ␤AR signaling may account for dysfunctional ␤AR vasorelaxation in hypertension rather than impaired endothelium-dependent nitric oxide metabolism. (Circulation. 2002;106:349-355.) 
A drenergic receptors (ARs) represent major regulators of the cardiovascular system. At the vascular level, ␣ and ␤ARs play a pivotal role in balancing vascular tone and blood pressure homeostasis. Vascular ␤ARs mediate adrenergic vasorelaxation through direct activation of vascular smooth muscle cells. However, recent data indicate that ␤ARdependent vasorelaxation is mediated, at least in part, by endothelium-and NO-dependent processes. 1, 2 Indeed, both ␤ 1 ARs and ␤ 2 ARs are expressed on endothelial cells, 3 and stimulation of endothelial ␤ 2 ARs causes endothelial nitric oxide synthase (eNOS) activation and NO release in human umbilical vein endothelium. 4 In hypertension, ␤AR control of vasorelaxation is impaired, and this impairment seems to be involved in high blood pressure. 5 There are two alternative hypotheses to explain this alteration. The first is that attenuated ␤AR vasorelaxation is the result of the general impairment of endothelial function observed in hypertension. Accordingly, changes in NO synthesis and availability affect proper vasorelaxation in response to several stimuli, including ␤AR stimulation. The second hypothesis involves the possibility that impaired vasorelaxation after ␤AR stimulation results directly from dysfunctional ␤AR signaling. Indeed, in hypertensive conditions, several reports indicate a reduction in ␤AR signaling and regulation. [5] [6] [7] [8] [9] [10] If these premises hold true, improving ␤AR signaling should result in the restoration of ␤AR vasorelaxation. In fact, some interventions have been effective in correcting ␤AR signaling in hypertension, such as dietary salt restriction 7 or pharmacological treatment. 11 Recently, a novel tool to modulate ␤AR signaling in a selective manner has been provided by adenoviral-mediated gene transfer of the human ␤ 2 AR cDNA. Indeed, in cardiac myocytes from both normal 12 and failing hearts, 13, 14 adenoviral-mediated delivery and overexpression of the ␤ 2 AR enhanced signaling and physiological responses to ␤AR agonists.
In this study, we sought to correct impaired ␤AR vasorelaxation in hypertension by adenoviral-mediated gene transfer of ␤ 2 ARs to the endothelium. First, in vitro in endothelial cells, we tested the effect of ␤ 2 AR stimulation on NO production. Then we evaluated in normotensive Wistar-Kyoto (WKY) rats the feasibility of in vivo gene transfer to the endothelium of the common carotid and whether ␤ 2 AR gene transfer can increase ␤AR vasorelaxation. Finally, we tested whether ␤ 2 AR gene transfer can correct impaired ␤AR vasorelaxation in the spontaneously hypertensive rat (SHR) model.
Methods

Adenoviral Constructs
We used a previously described adenovirus encoding for the human ␤ 2 AR (AD␤ 2 AR) and an empty viral vector (ADempty). [12] [13] [14] The viruses were suspended in PBS at Ϸ1ϫ10 10 plaque-forming units (pfu) per mL.
Primary Isolated Aortic Endothelial Cells and Arginine to Citrulline Conversion
Aortic endothelial cells were isolated from WKY rats (Charles River, Milan, Italy) and grown up to 6 passages as previously described. 15 Two days before the experiments, cells were incubated 30 minutes at 37°C with serum-free medium containing the virus at a multiplicity of infection of 100:1. NOS activity was assessed by the conversion of L-arginine into L-citrulline, which has a 1:1 stoichiometry to NO. Twenty-four hours after infection, equal numbers of cells were plated on 6-well plates and serum-starved overnight. The next day, cells were stimulated with isoproterenol (ISO) (10 Ϫ4 mol/L), ionomycin (2ϫ10 Ϫ3 mol/L in DMSO), or vehicle at 37°C for 30 minutes. Cells were homogenized in 25 mmol/L Tris HCl, ph7.4, 1 mmol/L EDTA, and 1 mmol/L EGTA; the pellet was collected after centrifugation; and 20 g of protein was incubated in 25 mmol/L Tris HCl, 3 mol/L tetrahydrobiopterin, 1 mol/L flavin adenine dinucleotide and 1 mol/L flavin adenine mononucleotide, 25 mol/L NADPH, 10 mol/L CaCl, and 2 nCi/L of [ 3 H] arginine for 60 minutes at 37°C. The reaction was stopped with equal volume of 50 mmol/L HEPES and 5 mmol/L EDTA and chromatographed on Dowex AG50WX-8 columns. Flow-throughs were counted by liquid scintillation. Citrulline production is expressed in pmol/mg of pellet protein/min.
Animals and Surgical Procedure
Twelve-week-old normotensive WKY and age-matched SHR rats were anesthetized with a mixture of ketamine (50 mg/kg) and xylazine (0.5 mg/kg), and the right external carotid was isolated and permanently closed with a nonreabsorbable suture placed as distally as possible. Common and internal carotids were clamped, and through an incision on the external carotid made proximal to the suture, a plastic cannula was advanced into the common carotid in a retrograde fashion. The virus (10 9 pfu in 100 L PBS) was then injected in the common carotid and allowed to incubate for 15 minutes. Afterward, the virus solution was removed, the external carotid closed proximally to the incision, and the blood flow restored through the common and internal carotid. A group of carotids received only PBS and represent the sham-operated control. After 3 days, the common carotids were harvested and used for histological, biochemical, or functional assessments. We chose this time course because it represents the earliest occurrence of overexpression of the viral vector. 14 The study was performed in accordance to the National Institutes of Health guidelines for animal studies.
␤ 2 AR Immunocytochemistry
Carotids of euthanized animals were immediately dissected out and frozen in isopentane chilled by liquid nitrogen. Cryostat sections 6 m thick were cut and mounted on poly-L-lysine-coated slides.
Sections were either kept frozen until use or fixed in cool acetone and dried. Nonspecific protein-binding sites on the tissue section were blocked by incubation with normal goat serum. This was followed, without additional washing, by incubation with 1:25 rabbit anti-␤ 2 AR (Santa Cruz Biotechnology, Santa Cruz, Calif) overnight at 4°C. An enzyme-labeled immunoreaction was carried out with a biotinylated secondary antibody followed by an avidin-conjugated alkaline phosphatase complex (Dako). Alkaline phosphatase was developed to give a red reaction product with naphthol AS-MX phosphate and new fuchsin in 0.1 mol/L Tris/HCl buffer, pH 8.2. Immunostaining controls consisted of substituting nonimmune serum for the primary antibody. Digital microphotographs were analyzed with ImageQuant 5.2 (Molecular Dynamics), and red staining intensity is expressed in arbitrary densitometric units.
␤AR Binding Assay
The rat carotid endothelium expresses both ␤ 1 ARs and ␤ 2 ARs 16 ; therefore, we measured the total number of ␤AR binding sites in carotid artery segments. Receptor binding was performed, partially modifying a previously described technique. 17 Common carotid segments were cut in 6 pieces of equal weight (100 to 200 g) to calculate B max and the nonspecific binding in triplicate. We used the nonselective ␤AR antagonist [ 125 I]-cyanopindolol as the ligand. Nonspecific binding was determined in the presence of 20 mol/L of the nonselective antagonist alprenolol. Reactions were conducted in 500 L of binding buffer (75 mmol/L Tris-Cl, pH 7.4, 12.5 mmol/L MgCl 2 , 2 mmol/L EDTA) at 37°C for 1 hour and then terminated by 3 washes in ice-cold binding buffer. Receptor density (fmol) was normalized to milligram of carotid weight. In a subset of carotids, endothelium was removed with a needle to verify the relevance of endothelium in the total number of ␤AR binding sites in whole carotid segments.
Vascular Reactivity Determined on Common Carotid Rings
After isolation, common carotids were suspended in isolated tissue baths filled with 25 mL Krebs solution (in mmol/L: NaCl 118.3, KCl 4.7, CaCl 2 2.5, MgSO 4 1.2, KH 2 PO 4 1.2, NaHCO 3 25, and glucose 5.6) continuously bubbled with a mixture of 5% CO 2 and 95% O 2 (pH 7.37 to 7.42) at 37°C. One end of the vessel was secured to a tissue holder and the other to an isometric force transducer connected to a Gould signal processor. The signal was analyzed by a computerized data acquisition system (Power Lab, ADI Instruments). Carotid arteries (Ϸ1 cm length) were pretensioned to 0.5 g. In pilot studies, we have found that this is the optimal preload for carotid responses. Vasoconstrictions to norepinephrine (NE) and epinephrine (EPI) were assessed by generating concentration response curves (10 Ϫ9 to 10 Ϫ6 mol/L and 10 Ϫ9 to 10 Ϫ5 mol/L, respectively). Vasorelaxation was assessed in vessel preconstricted with phenylephrine (PE) (10 Ϫ6 mol/L) in response to the ␤AR agonist ISO (10 Ϫ10 to 3ϫ10 Ϫ8 ), EPI (10 Ϫ9 to 10 Ϫ5 mol/L), or the ␣ 2 AR agonist brimonidine, also known as UK14,304 (10 Ϫ9 to 10 Ϫ5 mol/L) 15, 18 and sodium nitroprusside (10 Ϫ9 to 10 Ϫ5 mol/L). Drug concentrations are reported as the final molar concentration in the organ bath. Drugs were prepared daily in distilled water, except UK14,304, which was dissolved in DMSO and then diluted in water. The final DMSO-towater ratio (Ͼ0.01%) does not exert any vasoactive effect. 15
Results eNOS Activity in Primary Isolated Aortic Endothelial Cells From WKY Rats
To determine eNOS activity after ␤ 2 AR overexpression, primary aortic endothelial cells were infected with either ADempty or AD␤ 2 AR. eNOS activity was measured by citrulline accumulation basally and after stimulation with the ␤AR agonist ISO or the calcium ionophore ionomycin. This latter, by increasing intracellular calcium levels, can maximally activate eNOS. AD␤ 2 AR increases ISO-induced citrulline production without affecting basal or ionomycinstimulated NOS activity (Figure 1 ). Thus, under these in vitro conditions, ␤ 2 AR overexpression in endothelial cells results in apparent NO enhancement (Figure 1 ).
In Vivo Transgene Delivery and Expression
In the rat common carotid, transgene expression analysis was performed by immunocytochemistry ( Figure 2A ). Endogenous ␤ 2 AR distribution in control nontreated carotid arteries localizes at both endothelial cells and smooth muscle cells (Figure 2A, top) . In AD␤ 2 AR-treated carotids, overexpression of the ␤ 2 AR transgene predominates in the endothelium (Figure 2A, bottom) . Densitometry, performed on 5 sections from 3 carotids per group, revealed no difference in the expression of the ␤AR at the smooth muscle cell level between the AD␤ 2 AR and the control carotids (352Ϯ3 versus 331Ϯ3 densitometric units, respectively; not significant), whereas AD␤ 2 AR treatment almost doubled the ␤AR density at the endothelium when compared with control (498Ϯ2 versus 280Ϯ6 densitometric units, respectively; PϽ0.01). Similarly, using a ␤AR-binding assay, AD␤ 2 AR leads to an overall doubling of ␤AR receptor density when compared with control (either PBS or ADempty treatment) ( Figure 2B ). Moreover, this increase in ␤AR density was seen both in WKY and SHR carotids ( Figure 2B ). In endotheliumdenuded WKY carotids, no differences could be noted in the total ␤AR binding sites between AD␤ 2 AR and control carotids (0.44Ϯ0.1 versus 0.46Ϯ0.1 fmol/mg of carotid, respectively; nϭ5 for each group; Pϭnot significant).
Vasomotor Responses in WKY Rats
In carotid arteries from WKY rats, we tested the vascular responses to AR stimulations using PE, NE, and EPI as well as ISO, UK14,304, and the AR-independent vasodilator sodium nitroprusside. PE and NE vasoconstrictions were not affected ( Figure 3, A and B) , whereas EPI response was attenuated by AD␤ 2 AR ( Figure 3C ). Because vascular responses to EPI (␤ 2 Ͼ␣ 2 Ͼ␣ 1 ) result from the balance between ␣ 1 AR vasoconstriction and ␤ 2 AR vasorelaxation, impaired EPI vasoconstriction could result from the imbalance of these two opposing signals induced by the increased number of ␤ARs. Therefore, we tested whether in the AD␤ 2 AR carotids, the vasorelaxation to EPI is enhanced. Indeed, a clear vasorelaxation to EPI was observed in the AD␤ 2 AR carotids, 
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whereas EPI failed to induce any vasorelaxation in the control carotids ( Figure 4A ). The enhanced ␤AR vasorelaxation was also demonstrated by the observation that ISO-induced concentration-dependent vasorelaxation was doubled in the AD␤ 2 AR carotids ( Figure 4B ) compared with controls. It is possible to speculate that the ␤AR increased response could be attributable to ␤ 2 AR overexpression at the vascular smooth muscle level. This possibility is unlikely, because we used an intraluminal adenovirus delivery in absence of endothelial removal and basal lamina enzymatic digestion, which are needed for targeting vascular smooth muscle cells. 19 We performed two sets of experiments to ascertain the nature of ISO-induced vasorelaxation. As expected, 16 ␤AR vasorelaxation is largely endothelium-dependent, because the NOS inhibitor L NMMA (10 Ϫ5 mol/L) inhibited vasorelaxation to ISO to a similar extent in both the control and AD␤ 2 AR vessels ( Figure 4C ). This result was confirmed in endothelium-denuded carotids ( Figure 4D ). In addition, no difference was observed between AD␤ 2 AR and control carotids in the vasorelaxation to the ␣ 2 AR agonist UK14,304, an endothelium-dependent vasodilator ( Figure 4E ), or sodium nitroprusside, an endothelium-independent vasodilator ( Figure 4F ). Therefore, AD␤ 2 AR selectively enhanced ␤AR-stimulated endothelium-dependent vasorelaxation.
Vasomotor Responses in Spontaneously Hypertensive Rats
Control PE and NE vasoconstrictions were not different in carotid arteries of SHR and WKY rats, and AD␤ 2 AR treatment did not alter the maximal vasoconstriction responses to PE and NE in SHR rat carotid arteries ( Figure 5, A and B) . In SHR control-treated carotids, ␤AR-induced vasorelaxation was significantly impaired compared with that observed in WKY ( Figure 5C ). However, AD␤ 2 AR treatment resulted in the enhancement of the ISO-induced vasorelaxation ( Figure  5D ), which was actually similar to that observed in AD␤ 2 ARtreated WKY carotid arteries ( Figure 5E ). This response was specific for ␤AR-mediated effects because sodium nitroprusside induced a concentration-dependent vasorelaxation that did not differ between ADempty and AD␤ 2 AR carotids ( Figure 5F ).
Discussion
Our hypothesis is that by selectively enhancing signaling through one receptor system, it is possible to alter endothelial function and vascular responses. Indeed, a recent study 20 indicates that increasing intracellular signal transduction pathways can positively alter endothelial function. With this in mind, we speculated that by increasing ␤AR density we could increase vascular ␤AR responses. In umbilical vein endothelial cells, it has been demonstrated that ␤ 2 AR stimulates eNOS activation. 4 However, most studies in other preparations have failed to demonstrate an active release of NO in response to ␤AR agonists. 21 Therefore, we first confirmed that ISO in normotensive rat aorta endothelial cells can induce eNOS activation and also demonstrated that AD␤ 2 AR treatment can enhance this response. We then used adenoviral-mediated gene transfer of the human ␤ 2 AR to selectively target the endothelium in normotensive rat com- mon carotids. Our methods only allow a rough estimation of the relative density of endothelial versus vascular smooth muscle ␤ARs on treated and control carotids. However, this strategy enhanced the vascular response to ␤AR stimulation. Both eNOS inhibition and endothelial removal showed that the enhancement of vasorelaxation to ISO in AD␤ 2 ARtreated carotids is endothelium-dependent. Therefore, we exclude the hypothesis of adenoviral-mediated ␤ 2 AR overexpression in smooth muscle cells. These functional experiments together with ␤AR binding and immunocytochemistry indicate the selective targeting of the endothelium in the rat carotid by our gene transfer technique. Accordingly, this is the first demonstration that gene-targeted overexpression of the human ␤ 2 AR causes eNOS activation and endothelium NO-dependent vasorelaxation in the rat carotid.
The physiological relevance of endothelial ␤ 2 ARs is supported by their distribution in the vasculature. Evidence is mounting that ␤AR vasorelaxation is largely endotheliumdependent in a wide range of vascular districts that actively participate in the determination of total peripheral resistance, including skeletal muscle 2, 22 and mesenteric 23 and pulmonary vasculature systems. 24 Furthermore, in vivo studies in cat hind limb, 25 canine coronary artery, 26 and newborn pial arteries 27 suggest that the endothelium dependency of ␤AR vasorelaxant responses is generalized. Finally, recent studies in humans indicate that endothelial ␤ARs are totally, or at least predominantly, of the ␤ 2 AR subtype. 4, 22 The experiments in normotensive rats suggest a novel approach to correct impaired endothelial function in cardiovascular conditions. We speculated that by using the gene In the presence of the eNOS-inhibitor LNMMA (10 Ϫ5 mol/L) (C), there was no longer ISO vasorelaxation in both control and AD␤ 2 AR-treated carotids, suggesting that the ␤AR response is endothelium-dependent in both vessels. A similar result was observed when the endothelium was removed (D). The selective action of AD␤ 2 AR on the ␤-adrenergic responses is supported by the fact that the ␣ 2 AR endotheliumdependent vasorelaxation (E) as well as the nitroprusside endotheliumindependent vasorelaxation (F) were not affected by the AD␤ 2 AR treatment. ⅙ indicates control carotids; ⅷ, AD␤ 2 ARtreated carotids; nϭ6 to 12 per group; §Fϭ4.024; PϽ0.02. *Fϭ5.719, PϽ0.01; 2-way ANOVA.
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transfer of molecules that magnify intracellular signaling, it would be possible to correct abnormal vascular responses. We focused on ␤AR and hypertension because vascular ␤AR response is impaired in this condition and probably contributes to the progression of the disease. 28 Indeed, the combination of reduced ␤AR vasorelaxation and increased sympathetic nervous system activity is thought to participate in the increase of vascular resistance, vascular remodeling, and the increase of blood pressure levels. 5 Therefore, we aimed to increase ␤AR density by adenoviral-mediated gene transfer to the endothelium in hypertensive rats. A similar strategy in which the same virus was used has revealed efficacy to magnify ␤AR signaling and functional responses in vitro in cardiac myocytes from failing hearts. 13, 14 It is important to note that this strategy does not correct the biochemical impairment of ␤AR signaling but rather circumvents it by increasing the receptor number over physiological levels. In SHR carotids, AD␤ 2 AR magnified the physiological response to ␤AR stimulation and increased vasorelaxation to ISO without affecting other adrenergic responses or the intrinsic ability of the vessel to vasodilate in response to NO donors. Moreover, in AD␤ 2 AR-treated carotid arteries, no difference was observed between SHR and WKY. Thus, it seems that impaired ␤AR vasorelaxation in hypertension is directly related to dysfunctional ␤AR signaling.
In conclusion, endothelial ␤ 2 ARs may represent a target for correcting adrenergic endothelial dysfunction in hypertension, and genetic manipulation of endothelial ␤ 2 ARs may be a novel therapeutic strategy for hypertension. An important study supporting our conclusion is the recent finding that selective ␤ 2 AR-mediated increase of endothelial NO produc- Figure 5 . Effect of AD␤ 2 AR on the adrenergic vascular reactivity of common carotid arteries of SHR rats. As in normotensive rats, vasoconstriction to PE (A) and NE (B) were not affected by AD␤ 2 AR. In SHR, vasodilatation to ISO is attenuated compared with WKY (C). As in WKY, AD␤ 2 AR enhanced ISO vasorelaxation (D), which was not different from that observed in AD␤ 2 AR-treated WKY carotids (E). As in WKY, also in SHR, AD␤ 2 AR treatment did not affect the endothelium-independent vasorelaxation to nitroprusside (F). ▫ indicates WKY; Ⅲ, SHR; §Fϭ5.756; PϽ0.01; ⅙, control carotids; ⅷ, AD␤ 2 AR-treated carotids; nϭ6 to 10 per group. *Fϭ14.038, PϽ0.001; 2-way ANOVA.
